Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in …

K Kurose, E Sugiyama, Y Saito - Drug metabolism and …, 2012 - jstage.jst.go.jp
Drug lag, recently discussed extensively in Japan, can be divided into two phases: clinical
development time and application review time. The former factor is still an important problem …

[PDF][PDF] Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

…, R Fujii, S Watanabe, A Sai, S Fukuoka, E Sugiyama… - Cancer Cell, 2022 - cell.com
… The higher expression of MCT1 and LDHB was confirmed by western blotting (Figures S2E–S2H).
The analysis using chromatin immunoprecipitation sequencing (ChIP-seq) data in …

Identification of membrane-type receptor for bile acids (M-BAR)

…, T Nakamura, Y Tamai, H Okada, E Sugiyama… - Biochemical and …, 2002 - Elsevier
Bile acids play an essential role in the solubilization and absorption of dietary fat and lipid-soluble
vitamins. Bile acids also modulate the transcription of various genes for enzymes and …

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

S Kumagai, Y Togashi, T Kamada, E Sugiyama… - Nature …, 2020 - nature.com
Immune checkpoint blockade has provided a paradigm shift in cancer therapy, but the success
of this approach is very variable; therefore, biomarkers predictive of clinical efficacy are …

Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders

…, T Saeki, A Azumi, S Nakada, E Sugiyama… - Annals of the …, 2009 - ard.bmj.com
Background: Mikulicz’s disease (MD) has been considered as one manifestation of Sjögren’s
syndrome (SS). Recently, it has also been considered as an IgG 4 -related disorder. …

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer

E Sugiyama, Y Togashi, Y Takeuchi, S Shinya… - Science …, 2020 - science.org
… Here, Sugiyama et al. find that these tumors have an immunosuppressive tumor … Two
pathological researchers (E. Sugiyama and GI) independently evaluated the stained …

RFCPUs on glass and plastic substrates fabricated by TFT transfer technology

…, J Ishii, T Tsurume, E Sugiyama… - … Meeting, 2005. IEDM …, 2005 - ieeexplore.ieee.org
On the basis of the fabrication of a CPU on glass as a digital circuit presented in B. Lee et al.
(2003) and T. Ikeda et al. (2004), as well as the fabrication of a flexible CPU using a TFT …

[PDF][PDF] Peroxisome proliferator‐activated receptor α protects against alcohol‐induced liver damage

…, Y Kamijo, N Tanaka, E Sugiyama, E Tanaka… - …, 2004 - Wiley Online Library
The mechanisms underlying alcoholic liver disease are not completely understood, but lipid
accumulation seems to be central to the cause of this disease. The peroxisome …

Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high‐dose glucocorticoid, tacrolimus, and cyclophosphamide in …

…, S Hirata, T Nojima, E Sugiyama… - Arthritis & …, 2020 - Wiley Online Library
Sugiyama has received speaking fees from AbbVie, Asahi Kasei Pharma, Astellas Pharma,
AYUMI, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly, Janssen, Pfizer, Sanofi…

A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients

M Tohkin, N Kaniwa, Y Saito, E Sugiyama… - The …, 2013 - nature.com
Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe, cutaneous
adverse drug reactions that are rare but life threatening. Genetic biomarkers for allopurinol…